Hirsh, Vera <br/><br/>
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.  [electronic resource] 

 -  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer  Mar 2008 
 - 228-36 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1556-1380 
<br/><br/><label>Standard No.: </label>10.1097/JTO.0b013e3181651c0e  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Alkaline Phosphatase--blood<br/>Biomarkers, Tumor--urine<br/>Bone Density Conservation Agents--administration & dosage<br/>Bone Neoplasms--blood<br/>Canada--epidemiology<br/>Carcinoma, Non-Small-Cell Lung--metabolism<br/>Collagen Type I--drug effects<br/>Diphosphonates--administration & dosage<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Imidazoles--administration & dosage<br/>Lung Neoplasms--metabolism<br/>Male<br/>Middle Aged<br/>Osteoclasts--metabolism<br/>Peptides--drug effects<br/>Retrospective Studies<br/>Time Factors<br/>Treatment Outcome<br/>United States--epidemiology<br/>Zoledronic Acid